How would you treat a widely metastatic poorly differentiated pancreatic neuroendocrine cancer?
NCCN discusses targeted therapies (Everolimus) but also Temodar / Xeloda combination.
Answer from: Medical Oncologist at Academic Institution
The standard first line systemic therapy for poorly differentiated extrapulmonary neuroendocrine carcinoma (EP NEC) remains PE or platinum and etoposide (with some studies suggesting superiority of cis over carbo which likely reflects bias from patient characteristics). This is based on less than op...
Answer from: Medical Oncologist at Academic Institution
Tumor grade matters a great deal in pancreatic neuroendocrine tumors (PNET). When you are treating poorly differentiated, as opposed to well-differentiated or even moderately-differentiated, disease -- and especially when dealing with widely metastatic/high-volume situations -- I strongly favor star...
Comments
Medical Oncologist at UC Davis Cancer Center How many cycles of platinum/etoposide do you typic...